Future Directions, Community Collaboration, and Key Takeaways for Clinicians

The final segment looks ahead to future directions in follicular lymphoma management while emphasizing the essential partnership between academic and community practices. Dr. Mehta describes how evolving therapies, particularly bispecific antibodies, are increasingly being adopted in community settings, supported by collaborative frameworks that allow patients to receive advanced treatments while minimizing travel burdens. The faculty highlight ongoing clinical studies suggesting that bispecific antibodies may soon move into frontline settings for both follicular and large B-cell lymphoma. Dr. Mehta predicts that over the next several years, a majority of community practices will gain the capacity to deliver bispecific therapy independently, mirroring trends already seen in solid tumor settings. The discussion transitions to CD19-directed approaches, including tafasitamab and loncastuximab, and how these therapies complement CD20-based strategies. The importance of checking CD19 expression at relapse is emphasized when considering sequencing and future CAR T eligibility. In concluding remarks, Dr. Mehta outlines key messages for clinicians: R2 is no longer the standard of care in relapsed follicular lymphoma; newly approved regimens have demonstrated superior efficacy; and therapy selection should be guided by practice resources, patient goals, and toxicity profiles. The program ends with a forward-looking perspective on how novel therapeutics and collaborative care models will continue to elevate patient outcomes in relapsed/refractory follicular lymphoma.